Fig. 3: Swimmer plots showing the antitumor activity of pembrolizumab plus vorinostat by cancer type.

a, Head and neck cancer (N = 26 patients). b, Anal cancer (N = 29 patients). c, Cervical cancer (N = 23 patients). d, Vulvar/vaginal cancer (N = 16 patients). e, Penile cancer (N = 11 patients). No statistical test was used.